Most recently, SNAs targeting toll-like receptor 9 are being used in Phase 2 human trials via intratumoral injection to induce immune responses in Merkel cell and cutaneous squamous cell carcinoma. This evidence concerns the gene TLR9 and cutaneous squamous cell carcinoma.